



Nodus Oncology announces Dominic James as Chief Scientific Officer

Edinburgh, UK – 29/06/23 – Nodus Oncology, an emerging biotech company which is focused on developing first and best-in-class molecules inhibiting novel DDR targets, is delighted to announce the appointment of Dr Dominic James as Chief Scientific Officer (CSO).

Dominic has been part of the scientific advisory board (SAB) since 2022 and it is with great pleasure that we announce his appointment as CSO. “The appointment of Dominic is a great addition to the Nodus team” said Ian Waddell, CEO of Nodus Oncology.

Dominic has over 30 years’ experience in molecular and cellular biology with roles at the European Molecular Biology Laboratory, University of Geneva, AstraZeneca and the Cancer Research UK Manchester Institute (CRUK MI). He has successfully led drug discovery projects for CRUK MI from target identification through to licencing. Dominic is an enthusiastic and highly skilled scientist who was recently elected as a Fellow to the Royal Society of Biology. Most recently Dominic was VP of Translational Sciences at Imagen Therapeutics and was responsible for delivering all core CRO activities, supporting global business development operations, and delivering their publication strategy. Dominic's core interests lie in DNA damage response pathways, and in particular those involving PARG and PARP. He was instrumental in the delivery of first-in-class PARG inhibitors at CRUK MI.

About Nodus Oncology

Nodus Oncology is a biotech company developing first and best-in-class molecules focused on the DNA damage response (DDR) in patient sub-groups where molecular vulnerabilities exist. Founded by Cumulus Oncology, which contributes capital and oncology discovery and development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors. <http://www.nodusoncology.com>